Received May 5, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPIPV | DTAP + IPV (KINRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 34MF9 | — |
Kinrix out of the recommended age administration; Kinrix as fourth instead of fifth DTaP-IPV dose administration; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate age at vaccine administration in a 3-year-old male patient who received DTPa-IPV (Kinrix) (batch number 34MF9, expiry date 13-FEB-2026) for prophylaxis. On 16-APR-2025, the patient received Kinrix. On 16-APR-2025, an unknown time after receiving Kinrix, the patient experienced inappropriate age at vaccine administration (Verbatim: Kinrix out of the recommended age administration) and inappropriate schedule of vaccine administered (Verbatim: Kinrix as fourth instead of fifth DTaP-IPV dose administration). The outcome of the inappropriate age at vaccine administration and inappropriate schedule of vaccine administered were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 30-APR-2025 Certified Medical Assistant wanted to know if a Kinrix administration in a 3 years-old patient was considered an error and how to proceed, inappropriate age at vaccine administration. Also, agent asked in which number dose in the series for DTaP-IPV immunization Kinrix was given and the health care provider mentioned that was the fourth (instead of being the fifth, as recommended in the prescribing information), which led to inappropriate schedule of vaccine administered. The Vaccine Administration Facility is the same as Primary Reporter. The reporter consented to follow up.